MaxCyte confirmed on Wednesday that trading of its shares on London’s AIM market would cease at the close of trading, with the cancellation of its AIM listing taking effect at 0700 BST on Thursday.
Maxcyte (DI)
25 June 2025 12:33:06
Source: Sharecast
It said the decision followed shareholder approval at the company’s annual general meeting on 18 June.
The cell engineering company, which provides platform technologies for the development of next-generation cell therapeutics, said it would retain its listing on the Nasdaq Global Select Market in the United States, where its shares would continue to trade under the ticker MXCT.
MaxCyte noted that following the delisting, there would no longer be a public market in the UK for its common stock.
At 1149 BST, shares in MaxCyte were down 5.94% in London, at 150.5p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
